Company: AZN
Filing Date: 2025-12-16
Form Type: 6-K
Source: 0001654954-25-013974
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-12-16
Form: 6-K
Chunk 7
---
: basic concepts and clinical relevance in immune-mediated inflammatory diseases. Gene . 2016;576(101):14-21.

26. Rönnblom L, et al. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med . 2019;6(1):e000270.

27. Mosca M, et al. Attainment of LLDAS and DORIS remission during anifrolumab treatment: interim results from a multinational, observational, post-launch study of treatment effectiveness in the real world. Ann Rheum Dis . 2025. 84(1):168-169.

28. Morand EF, et al. LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. Ann Rheum Dis . 2025; 84(5): 777-778.

29. Vollenhoven R, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science & Medicine . 2021; 8: e000538. doi:10.1136/ lupus-2021-000538.

30. Clinicaltrials.gov. A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/ or Subacute Cutaneous Lupus Erythematosus (LAVENDER). Available at: https://clinicaltrials.gov/study/NCT06015737 . [Last accessed: December 2025].

31. Clinicaltrials.gov. A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) (JASMINE). Available at: https://clinicaltrials.gov/study/NCT06455449 . [Last accessed: December 2025].

32. Clinicaltrials.gov. Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY). Available at: https://clinicaltrials.gov/study/NCT05925803 . [Last accessed: December 2025].

33. ClinicalTrials